Key Figures Q2 2022
|
SEK m, unless otherwise stated |
2022 Apr-Jun |
2021 Apr-Jun |
2022 Jan-Jun |
2021 Jan-Jun |
% Change |
2021 Jan-Dec |
|
Net revenues |
147.8 |
142.8 |
307.3 | 275.1 | 3.5% |
565.0 |
|
Cost of goods sold |
-21.2 |
-18.1 |
-48.7 | -37.4 | 17.5% |
-78.9 |
|
Operating expenses |
-176.4 |
-178.7 |
-321.5 | -328.7 | -1.3% |
-700.2 |
|
EBIT |
-49.7 |
-54.0 |
-62.9 | -90.9 | 7.9% |
-214.1 |
|
EBIT margin, % |
-33.6% |
-37.8% |
-20.5% | -33.1% | 4.2% |
-37.9% |
|
EBITDA |
-32.5 |
-41.1 |
-29.7 | -65.2 | 20.9% |
-161.0 |
|
Earnings per share, before dilution, SEK |
-1.04 |
-2.15 |
-1.73 | -3.07 | 51.6% |
-6.51 |
|
Earnings per share, after dilution, SEK |
-1.04 |
-2.15 |
-1.73 | -3.07 | 51.6% |
-6.51 |
|
Cash flow from operating activities |
14.5 |
-20.9 |
-47.1 | -68.7 | 169.5% |
-229.0 |
|
Cash and cash equivalents |
467.7 |
679.7 |
467.7 | 679.7 | -31.2% |
504.1 |
Net revenues and EBIT per segment Q2 2022
| SEK m | Net Revenues | EBIT | ||||||||
| 2022 Apr-Jun | 2021 Apr-Jun | 2022 Jan-Jun | 2021 Jan-Jun | 2021 Jan-Dec | 2022 Apr-Jun | 2021 Apr-Jun | 2022 Jan-Jun | 2021 Jan-Jun | 2021 Jan-Dec | |
| ZUBSOLV® US | 139.6 | 126.0 | 278.7 | 252.8 | 522.7 | - | - | - | - | - |
| US Pharma – total | 139.6 | 126.0 | 278.7 | 252.8 | 522.7 | 77.2 | 61.6 | 161.2 | 127.7 | 278.2 |
| Digital Therapeutics (DTx) product sales | 0.1 | 0.3 | 0.3 | 0.4 | 1.1 | - | - | - | - | - |
| Digital Therapeutics (DTx) – total | 0.1 | 0.3 | 0.3 | 0.4 | 1.1 | -47.9 | -51.6 | -91.3 | -110.5 | -249.7 |
| Abstral® royalties | 5.0 | 14.3 | 17.4 | 17.0 | 32.1 | - | - | - | - | - |
| Edluar® royalties | 1.6 | 2.3 | 4.8 | 4.9 | 9.1 | - | - | - | - | - |
| ZUBSOLV® - ex US | 1.5 | - | 6.1 | - | - | - | - | - | - | - |
| HQ & Pipeline segment - total | 8.1 | 16.5 | 28.3 | 21.9 | 41.2 | -79.1 | -63.9 | -132.9 | -108.2 | -242.6 |
| Total | 147.8 | 142.8 | 307.3 | 275.1 | 565.0 | -49.7 | -54.0 | -62.9 | -90.9 | -214.1 |
Cash flow Q2 2022
|
SEK m |
2022 Apr-Jun |
2021 Apr-Jun |
2022 Jan-Jun |
2021 Jan-Jun |
2021 Jan-Dec |
|
Cash flow from operating activities |
14.5 |
-20.9 |
-47.1 |
-68.7 |
-299.0 |
|
Investment activities |
-226.3 |
-13.1 |
-231.9 |
-29.3 |
-52.9 |
|
Financing activities |
-5.3 |
-3.5 |
-10.6 |
258.2 |
250.6 |
|
Cash flow (excl exchange rate differences) |
-217.0 |
-37.5 |
-289.6 |
160.1 |
-31,2 |
|
Liquid funds |
244.2 |
679.7 |
244.2 |
679.7 |
504.1 |